Table of Content


Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Biosimilars dealmaking

2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Deal terms for biosimilars partnering
2.6.1 Biosimilars partnering headline values
2.6.2 Biosimilars deal upfront payments
2.6.3 Biosimilars deal milestone payments
2.6.4 Biosimilars royalty rates

Chapter 3 – Leading Biosimilars deals

3.1. Introduction
3.2. Top Biosimilars deals by value

Chapter 4 – Most active Biosimilars dealmakers

4.1. Introduction
4.2. Most active Biosimilars dealmakers
4.3. Most active Biosimilars partnering company profiles

Chapter 5 – Biosimilars contracts dealmaking directory

5.1. Introduction
5.2. Biosimilars contracts dealmaking directory

Chapter 6 – Biosimilars dealmaking by technology type

Appendices

Appendix 1 – Biosimilars deals by company A-Z
Appendix 2 – Biosimilars deals by stage of development
Appendix 3 – Biosimilars deals by deal type
Appendix 4 – Biosimilars deals by therapy area
Appendix 5 – Deal type definitions
Appendix 6 – Further reading

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
?
Table of figures

Figure 1: Biosimilars partnering since 2010
Figure 2: Active biosimilars dealmaking activity since 2010
Figure 3: Biosimilars partnering by deal type since 2010
Figure 4: Biosimilars partnering by disease type since 2010
Figure 5: Biosimilars partnering by technology type since 2010
Figure 6: Biosimilars deals with a headline value
Figure 7: Biosimilars deals with an upfront value
Figure 8: Biosimilars deals with a milestone value
Figure 9: Biosimilars deals with a royalty rate value
Figure 10 Top biosimilars deals by value since 2010
Figure 11: Most active biosimilars dealmakers since 2010